By Colin Kellaher

AbbVie Inc. on Thursday said it won a key court ruling that could keep generic versions of the blockbuster blood-cancer drug Imbruvica from hitting the U.S. market for more than a decade.

The North Chicago, Ill., biopharmaceutical company said a U.S. District Court ruled that patent rights owned by AbbVie's Pharmacyclics LLC unit related to Imbruvica are valid and infringed by a generic product from Alvogen Pine Brook LLC and Natco Pharma Ltd.

AbbVie, which jointly develops and markets Imbruvica with Johnson & Johnson's Janssen Biotech Inc. unit, said the court's ruling, which is subject to appeal, prohibits regulatory approval of the Alvogen/Natco product until the last patent expires.

AbbVie, which has previously inked several settlement and license agreements with other generic drug makers related to Imbruvica, said it doesn't expect a generic entry before March 2032, assuming the companies gain pediatric exclusivity for the drug.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

August 19, 2021 14:28 ET (18:28 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Johnson and Johnson (NYSE:JNJ)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Johnson and Johnson
Grafico Azioni Johnson and Johnson (NYSE:JNJ)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Johnson and Johnson